快而精医药(Qiagen NV)宣布,其高通量Qiastat-Dx Rise系统已获得美国监管部门批准,这将扩大患者获得快速综合征检测的机会。
这一新获批的系统代表着该公司在诊断技术领域的重要进展,能够为医疗机构提供更高效的检测解决方案,进一步提升患者的诊疗体验和医疗服务质量。
快而精医药(Qiagen NV)宣布,其高通量Qiastat-Dx Rise系统已获得美国监管部门批准,这将扩大患者获得快速综合征检测的机会。
这一新获批的系统代表着该公司在诊断技术领域的重要进展,能够为医疗机构提供更高效的检测解决方案,进一步提升患者的诊疗体验和医疗服务质量。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.